KnowBreastCancer StopBreastCancer Learn the Facts. Know the Evidence. Become an Advocate. Brought to you by NBCC
 

SABCS 2011: New Test Predicts Risk for Recurrence for Patients with DCIS

A multigene test can differentiate lower-risk and more aggressive forms of ductal carcinoma in situ (DCIS), according to results presented at the 34th Annual CTRC-AACR San Antonio Breast Cancer Symposium. In a collaboration between the Eastern Cooperative Oncology Group (ECOG), North Central Cancer Treatment Group and Genomic Health, researchers used the Oncotype DX breast cancer […]

IOM Releases Report on Breast Cancer and the Environment

The Institute of Medicine (IOM) released a new report today, entitled “Breast Cancer and the Environment: A Life Course Approach.” The report, which was sponsored by Susan G. Komen for the Cure, was released during a press conference at the 34th Annual CTRC-AACR San Antonio Breast Cancer Symposium. In this report, the IOM reviews the […]

SABCS 2011: Zoledronic Acid Shows Long-Term Benefit in Survivorship for Premenopausal ER-Positive Breast Cancer

Zoledronic acid and endocrine treatment improved both disease-free and overall survival in early-stage, premenopausal ER-positive breast cancer, according to study results presented at the 34th Annual CTRC-AACR San Antonio Breast Cancer Symposium. Researchers from the Austrian Breast & Colorectal Cancer Study Group (ABCSG-12) presented their results after a median of 76 months of follow-up, confirming […]

Personalizing Mammography by Breast Density and Other Risk Factors

The results of an analysis estimating the cost-effectiveness of mammography by age, breast density (the strongest risk factor for breast cancer), history of breast biopsy, family history of breast cancer, and screening interval were published this week in the Annals of Internal Medicine. Based on the results, the authors recommend that all women have an […]

Overall Survival as Endpoint

A commentary published recently in the Journal of Clinical Oncology by Dr. Edward Korn of the NCI, discusses the use of overall survival (OS) as the measure of clinical benefit. This review is divided into three sections, beginning first with situations where identical subsequent therapy is used after both treatment arms and is either differentially […]

Impact of BMI on Response to Endocrine Therapy

Study Design: A retrospective analysis of data from a prospective trial of premenopausal women. The original data came from the Austrian Breast and Colorectal Cancer Study Group 12 (ABCSG-12). This study compared the endocrine treatment of goserelin with tamoxifen versus anastrozole in premenopausal patients with endocrine-responsive breast cancer. Study Eligibility: Premenopausal women with hormone-receptor-positive (estrogen-receptor […]

Health Outcomes After Stopping Estrogen Alone Hormone Replacement Therapy Among Postmenopausal Women With Prior Hysterectomy

Follow up results from the Women’s Health Initiative Study Design: Women’s Health Initiative (WHI) Estrogen-Alone Trial was a double-blind, placebo-controlled randomized trial of conjugated equine estrogens (CEE) versus placebo. Study Eligibility: Postmenopausal women aged 50-79 years who had a prior hysterectomy, were not taking hormone therapy and had had an anticipated 3-year survival or more. […]

Duration of Chemotherapy for Metastatic Breast Cancer

Study Design: Systematic review of randomized controlled trials comparing shorter versus longer first-line chemotherapy duration in patients with metastatic breast cancer (MBC). Study Eligibility: Eligible trials of first-line chemotherapy in MBC patients included: trials comparing a fixed number of cycles versus continuation of the same chemotherapy (CT) until disease progression; trials comparing a fixed number […]

Two randomized trials on DCIS treatment: fifteen year followup

Study Design: Two prospective randomized trials conducted by the National Surgical Adjuvant Breast and Bowel Project (NSABP). In the first trial, NSABP B-17, patients with localized DCIS were randomly assigned to lumpectomy only (LO) group or lumpectomy followed by radiation (LRT). The second trial, NSABP B-24, was a double-blinded, placebo-controlled trial that compared LRT + […]

Advanced breast cancer incidence following population-based mammographic screening

Study Design: Systematic review of published data from January 1990 to June 2009 on incidence trends of advanced breast cancer in areas with mammography screening for at least 7 years and high rates of screening participation. Data from the literature was supplemented with data from several population-based cancer registries. Study Eligibility: Data or studies that […]